{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:51:00Z","timestamp":1791442260692,"version":"4.3.3"},"reference-count":13,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.cllc.2026.08.013","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:04:19Z","timestamp":1789052659000},"page":"20-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low Baseline Absolute Neutrophil Count and Chemotherapy Safety in African American Patients with Advanced Lung Cancer: A Retrospective Cohort Study"],"prefix":"10.1016","volume":"27","author":[{"given":"Mumtu","family":"Lalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simo","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajvi","family":"Gor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Narvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"D\u2019Aiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeevan","family":"Shivakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasiya","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina Martins","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.","family":"Beumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6051-2732","authenticated-orcid":false,"given":"Haiying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.cllc.2026.08.013_bib0001","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1001\/jama.2023.7467","article-title":"Development of Duffy null-specific absolute neutrophil count reference ranges","volume":"329","author":"Merz","year":"2023","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.cllc.2026.08.013_bib0002","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.htct.2020.08.015","article-title":"Duffy phenotyping and FY*B-67T\/C genotyping as screening test for benign constitutional neutropenia","volume":"43","author":"Barreto","year":"2021","journal-title":"Hematol Transfus Cell Ther"},{"issue":"2","key":"10.1016\/j.cllc.2026.08.013_bib0003","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0002-9343(79)90391-7","article-title":"Marrow granulocyte reserves in black Americans. Hydrocortisone-induced granulocytosis in the \"benign\" neutropenia of the black","volume":"67","author":"Mason","year":"1979","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.cllc.2026.08.013_bib0004","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/bloodadvances.2024014399","article-title":"Characterization of the phenotypic consequences of the Duffy-null genotype","volume":"9","author":"Hysong","year":"2025","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.cllc.2026.08.013_bib0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.2025029359","article-title":"Multinational assessment of absolute neutrophil counts and white blood cell counts among healthy Duffy-null adults","volume":"147","author":"Hibbs","year":"2026","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cllc.2026.08.013_sbref0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.32475","article-title":"Cancer trial eligibility and therapy modifications for individuals with Duffy null-associated neutrophil count","volume":"7","author":"Hibbs","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cllc.2026.08.013_bib0007","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hematopoietic Growth Factors. Version 3.2026.Plymouth Meeting (PA): National Comprehensive Cancer Network; 2026. Available from https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf."},{"issue":"6","key":"10.1016\/j.cllc.2026.08.013_bib0008","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/bloodadvances.2021005482","article-title":"Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials","volume":"6","author":"Kanapuru","year":"2022","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.cllc.2026.08.013_bib0009","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1002\/cncr.33620","article-title":"Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer","volume":"127","author":"Lynce","year":"2021","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.013_bib0010","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/bloodadvances.2024014255","article-title":"Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival","volume":"9","author":"Avigan","year":"2025","journal-title":"Blood Adv"},{"issue":"21","key":"10.1016\/j.cllc.2026.08.013_bib0011","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2409329","article-title":"The Duffy null phenotype - addressing a source of discrimination in cancer care","volume":"391","author":"Hantel","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.cllc.2026.08.013_bib0012","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1001\/jamaoncol.2025.3869","article-title":"Duffy null-associated absolute neutrophil counts and cancer clinical trial eligibility","volume":"11","author":"Merz","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cllc.2026.08.013_bib0013","unstructured":"American Society of Hematology. Duffy status assessment in clinical trials. Washington DC: American Society of Hematology;2025. Available from: https:\/\/www.hematology.org\/-\/media\/hematology\/files\/education\/duffy-null-pdf.pdf."}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573042600118X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573042600118X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:13:02Z","timestamp":1791439982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152573042600118X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S152573042600118X"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.08.013","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low Baseline Absolute Neutrophil Count and Chemotherapy Safety in African American Patients with Advanced Lung Cancer: A Retrospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}